Sun Pharma bucks the trend
India’s largest pharma company has caught investors’ fancy and a lot of it is due to founder Dilip Shanghvi’s need to take a different path.
Why read this story?
Editor's note: Sun Pharmaceutical Industries’s market capitalization is back at Rs 240,000 crore. That’s just 12% shy of its best ever market capitalization of Rs 269,000 crore, which it hit in March 2015, making its founder Dilip Shanghvi India’s richest person for a brief while before Reliance Industries’s Mukesh Ambani took back the crown. What makes the Sun Pharma stock stand out is that it has gained 18.3% in the last one year, at a time when the healthcare industry, represented by the BSE Healthcare index, fell 11.85%. Sun Pharma has also significantly outperformed the broader Nifty 50, which has risen 2.4% in the same time. The good run is likely to continue for India’s largest pharma company, as most analysts are upbeat about its prospects in the year ahead, even as they forecast a poor run for the pharma sector as a whole. After recovering to its pre-COVID levels in April 2021, the SunPharma stock has only gained ground thereafter, and is now close to its seven-year high. For the 2021-22 financial year, the company’s operating profits stood at Rs 10,258 …
More in Business
You may also like
The weight-loss wave that’s changing India—one sector at a time
Mounjaro’s blockbuster debut has already sparked a seismic shift across Indian healthcare, diagnostics and pharma. A marked change in consumer behaviour looks imminent.
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
For Sun Pharma’s Dilip Shanghvi, specialty drugs remain the magic bullet
Specialty drugs are fast becoming a lucrative market globally. And India’s largest drugmaker has done well to make the most of this opportunity so far. But it’s too soon to rest easy.